Microbio's postbiotic MS-20 achieved 83.3% clinical remission rate in ulcerative colitis patients when added to standard treatments, compared to 35.7% with placebo, demonstrating statistically significant improvement (p=0.021).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.